ETV6 also was frequently deleted in TP53-mutated samples in the Beat AML cohort[28] with loss of one copy of ETV6 in 6/19 (32%) cases, compared to 4/238 (1.7%) of non-TP53 mutated primary AML samples (OR=26, 95% CI=(5.4, 141.9), p=1.3×10−5, 2-sided Fisher’s exact test, Supplementary Table 9). Here, TP53 is linked to acute myeloid leukemia.